These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 2787699

  • 1. Human recombinant interleukin 2-activated sheep lymphocytes lyse sheep pulmonary microvascular endothelial cells.
    Duke SS, King LS, Jones MR, Newman JH, Brigham KL, Forbes JT.
    Cell Immunol; 1989 Aug; 122(1):188-99. PubMed ID: 2787699
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Activated endothelial cells resist lymphokine-activated killer cell-mediated injury. Possible role of induced cytokines in limiting capillary leak during IL-2 therapy.
    Mier JW, Brandon EP, Libby P, Janicka MW, Aronson FR.
    J Immunol; 1989 Oct 01; 143(7):2407-14. PubMed ID: 2528594
    [Abstract] [Full Text] [Related]

  • 4. Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice.
    Ettinghausen SE, Puri RK, Rosenberg SA.
    J Natl Cancer Inst; 1988 Apr 06; 80(3):177-88. PubMed ID: 3258039
    [Abstract] [Full Text] [Related]

  • 5. Chronic interleukin-2 treatment in awake sheep causes minimal or no injury to the lung microvascular barrier.
    Jerome EH, Enzan K, Douguet D, Lei D, Jesmok G, Johnson CW, Neuburger M, Staub NC.
    J Appl Physiol (1985); 1996 Oct 06; 81(4):1730-8. PubMed ID: 8904593
    [Abstract] [Full Text] [Related]

  • 6. Toxicity and immunologic effects of continuous infusion of recombinant human interleukin-2 administered by selective hepatic perfusion in dogs.
    Da Pozzo LF, Hough KL, Holder WD.
    Surgery; 1992 Mar 06; 111(3):326-34. PubMed ID: 1542858
    [Abstract] [Full Text] [Related]

  • 7. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
    Flexman JP, Manning LS, Robinson BW.
    Clin Exp Immunol; 1990 Oct 06; 82(1):151-6. PubMed ID: 2208789
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. In vivo interleukin-2 activated sheep lung lymph lymphocytes increase ovine vascular endothelial permeability by non-lytic mechanisms.
    Bechard DE, Fairman RP, Hinshaw DB, Fowler AA, Glauser FL.
    Eur J Cancer; 1990 Oct 06; 26(10):1074-8. PubMed ID: 2148883
    [Abstract] [Full Text] [Related]

  • 10. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ, Yang J, Shu S, Rosenberg SA.
    J Immunol; 1986 May 15; 136(10):3899-909. PubMed ID: 2871106
    [Abstract] [Full Text] [Related]

  • 11. Human recombinant interleukin-2 provokes acute pulmonary vascular endothelial injury in rabbits.
    Goldblum SE, Yoneda K, Cibull M, Pearson T, Hall C, Marshall ME.
    J Biol Response Mod; 1990 Apr 15; 9(2):127-39. PubMed ID: 2160520
    [Abstract] [Full Text] [Related]

  • 12. Role of asialo-GM1-positive lymphoid cells in mediating the toxic effects of recombinant IL-2 in mice.
    Gately MK, Anderson TD, Hayes TJ.
    J Immunol; 1988 Jul 01; 141(1):189-200. PubMed ID: 3259967
    [Abstract] [Full Text] [Related]

  • 13. Interferon-gamma protects human endothelial cells from lymphokine-activated killer cell-mediated lysis.
    Renkonen R, Ristimäki A, Häyry P.
    Eur J Immunol; 1988 Nov 01; 18(11):1839-42. PubMed ID: 3144455
    [Abstract] [Full Text] [Related]

  • 14. Lymphokine activated killer (LAK) cell-mediated endothelial injury: a mechanism for capillary leak syndrome in patients treated with LAK cells and interleukin-2.
    Kotasek D, Vercellotti GM, Ochoa AC, Bach FH, Jacob HS.
    Trans Assoc Am Physicians; 1987 Nov 01; 100():21-7. PubMed ID: 3502662
    [Abstract] [Full Text] [Related]

  • 15. Mechanism of cultured endothelial injury induced by lymphokine-activated killer cells.
    Kotasek D, Vercellotti GM, Ochoa AC, Bach FH, White JG, Jacob HS.
    Cancer Res; 1988 Oct 01; 48(19):5528-32. PubMed ID: 3262010
    [Abstract] [Full Text] [Related]

  • 16. Lymphokine-activated killer (LAK) cell activity in tumor-infiltrating lymphocytes from non-small cell lung cancer.
    Pisani RJ, Krco CJ, Wold LE, McKean DJ.
    Am J Clin Pathol; 1989 Oct 01; 92(4):435-46. PubMed ID: 2552792
    [Abstract] [Full Text] [Related]

  • 17. Perilla ketone: a model of increased pulmonary microvascular permeability pulmonary edema in sheep.
    Coggeshall JW, Lefferts PL, Butterfield MJ, Bernard GR, Carroll FE, Pou NA, Snapper JR.
    Am Rev Respir Dis; 1987 Dec 01; 136(6):1453-8. PubMed ID: 3688648
    [Abstract] [Full Text] [Related]

  • 18. Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity.
    Brooks B, Rees RC.
    Clin Exp Immunol; 1988 Nov 01; 74(2):162-5. PubMed ID: 3265652
    [Abstract] [Full Text] [Related]

  • 19. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
    Ochoa AC, Hasz DE, Rezonzew R, Anderson PM, Bach FH.
    Cancer Res; 1989 Feb 15; 49(4):963-8. PubMed ID: 2521457
    [Abstract] [Full Text] [Related]

  • 20. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
    Owen-Schaub LB, Gutterman JU, Grimm EA.
    Cancer Res; 1988 Feb 15; 48(4):788-92. PubMed ID: 3257408
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.